4.6 Article

Long-term eltrombopag for bone marrow failure depletes iron

Journal

AMERICAN JOURNAL OF HEMATOLOGY
Volume 97, Issue 6, Pages 791-801

Publisher

WILEY
DOI: 10.1002/ajh.26543

Keywords

-

Categories

Funding

  1. GlaxoSmithKline
  2. Novartis

Ask authors/readers for more resources

EPAG treatment for aplastic anemia and immune thrombocytopenia can result in iron depletion over time. This study found that duration of EPAG exposure correlated with reduction in ferritin levels and showed faster iron clearance compared to historical responders. Baseline ferritin and duration of therapy were associated with risk of iron depletion, but did not affect treatment response or relapse risk.
Eltrombopag (EPAG) has been approved for the treatment of aplastic anemia and for immune thrombocytopenia, and a subset of patients require long-term therapy. Due to polyvalent cation chelation, prolonged therapy leads to previously underappreciated iron depletion. We conducted a retrospective review of patients treated at the NIH for aplastic anemia, myelodysplastic syndrome, and unilineage cytopenias, comparing those treated with EPAG to a historical cohort treated with immunosuppression without EPAG. We examined iron parameters, duration of therapy, response assessment, relapse rates, and common demographic parameters. We included 521 subjects treated with (n = 315) or without EPAG (n = 206) across 11 studies with multiyear follow-up (3.6 vs. 8.5 years, respectively). Duration of EPAG exposure correlated with ferritin reduction (p = 4 x 10(-14)) regardless of response, maximum dose, or degree of initial iron overload. Clearance followed first-order kinetics with faster clearance (half-life 15.3 months) compared with historical responders (47.5 months, p = 8 x 10(-10)). Risk of iron depletion was dependent upon baseline ferritin and duration of therapy. Baseline ferritin did not correlate with response of marrow failure to EPAG or to relapse risk, and timing of iron clearance did not correlate with disease response. In conclusion, EPAG efficiently chelates total body iron comparable to clinically available chelators. Prolonged use can deplete iron and ultimately lead to iron-deficiency anemia mimicking relapse, responsive to iron supplementation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available